Bausch Health Companies Inc. (TSX:BHC)
Canada · Delayed Price · Currency is CAD | Market Cap | 3.72B |
| Revenue (ttm) | 13.44B |
| Net Income (ttm) | 133.66M |
| Shares Out | n/a |
| EPS (ttm) | 0.36 |
| PE Ratio | 27.84 |
| Forward PE | 1.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 229,611 |
| Average Volume | 417,455 |
| Open | 10.04 |
| Previous Close | 10.04 |
| Day's Range | 9.86 - 10.11 |
| 52-Week Range | 5.91 - 13.74 |
| Beta | 0.48 |
| RSI | 53.15 |
| Earnings Date | Nov 6, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews
Bausch Health: Repricing Continues As Deleveraging Gains Traction
Bausch Health (BHC) Completes Acquisition of DURECT Corporation
Bausch Health (BHC) Completes Acquisition of DURECT Corporation
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV...
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV...
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Ameri...
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophth...
Bausch Health's Thermage Technology Reaches 5 Million Treatment Milestone | BHC stock news
Bausch Health's Thermage Technology Reaches 5 Million Treatment Milestone | BHC stock news
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin ...
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System | BHC Stock News
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aest...
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) t...
Carl Icahn's Complete Divestment from Bausch Health Companies Inc
Carl Icahn's Complete Divestment from Bausch Health Companies Inc
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that...
A Look Into Bausch Health Companies Inc's Price Over Earnings
In the current session, the stock is trading at $7.81, after a 0.26% increase. Over the past month, Bausch Health Companies Inc. (NYSE: BHC) stock increased by 14.81% , and in the past year, by 32.32...
Bausch + Lomb board members resign after Icahn agreement ends
Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.
Alembic Pharma shares jump over 2% as USFDA approves Tretinoin Cream USP
Shares of Alembic Pharmaceuticals gained over 2% on Monday, August 19, after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbrevia...
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and...
Bausch Health rises after $300M worth insider purchase
Why Bausch Health Stock Surged By Nearly 20%
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BH...
Bausch Health Companies Inc. 2025 Q2 - Results - Earnings Call Presentation
Bausch Health reaffirms 2025 revenue target of $4.95B–$5.1B as debt reduction and pipeline expansion advance
Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executiv...
Bausch Health Companies GAAP EPS of $0.40 beats by $0.36, revenue of $2.53B beats by $40M
Bausch Health Announces Second Quarter 2025 Results
Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health Compani...
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health Companies Inc. (NYSE: BHC) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ: DRRX), including a novel therapeutic molecule, larsucosterol . Larsucosterol, an endogenous sulf...